← Human Trials & Peer-Reviewed Studies
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Plain-language guide to NCT06896422: phase 1 randomized trial of Glutathione, 80 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06896422
- Phase
- phase 1
- Status
- recruiting participants
- Start
- 2025-06-01
- Completion (planned or actual)
- 2026-12-31
- Participants
- 80 (estimated)
- Design
- randomized, open label (everyone knows who gets what), prevention
- Conditions studied
- Non-Small Cell Lung Cancer; Chemotherapy; PD1 Antibody; Glutathione
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 1) is built around Glutathione.
It had two arms (groups): PD-1 inhibitor plus chemotherapy arm (placebo comparator) and Glutathione combined with PD-1 inhibitor plus chemotherapy arm (experimental).
The registry classes the interventions as drug.
Who Took Part
Enrollment: 80 planned participants were the target.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Histologically or cytologically confirmed diagnosis of lung squamous cell carcinoma or adenocarcinoma. Age ≥18 years at the time of enrollment.
The full record lists 3 inclusion and 3 exclusion criteria; among the exclusions: patients with small cell lung cancer or other histological subtypes of lung cancer; pregnant or lactating women.
How the Study Was Run
It was run as a randomized, parallel-group and open-label study.
The participants were allocated by chance, so the Glutathione group and the comparison group should start out alike.
The Glutathione group and the comparison group ran side by side rather than switching.
Everyone knew when Glutathione was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
It started in 2025-06-01 with completion listed for 2026-12-31.
It ran at 1 site in China.
Its stated primary purpose is prevention.
What Was Measured
The main thing measured (primary outcome): Progression-Free Survival (PFS). Overall Response Rate (ORR) (time frame: From the initiation of treatment until 12 weeks).
It also tracked 3 secondary outcomes, for example QLQ-LC43 and Overall survival.
What This Means in Plain Language
Put simply, this is a phase 1, randomized trial of Glutathione in 80 people.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Glutathione compound page, all human trials.
Our Notes on the Compound
Glutathione: The body's main antioxidant.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.